About Codexis
Codexis is a publicly listed company based in Redwood City (United States) founded in 2002. High-performance enzymes are developed for drug discovery and biotherapeutics. Codexis has raised $74.17 million across 9 funding rounds from investors including Chevron, FirstMark and Maxygen. The company has 188 employees. Its chief executive, as recorded, is Stephen Dilly. Codexis offers products and services including CodeEvolver Platform and ECO Synthesis Technology. Its focus areas include Life Sciences, Genomics, Applied Genomics and Synthetic Biology. Its legal entity in India is Codexis Laboratories India Private Limited (U24231KA2005PTC035895). Its competitors include Amyris, AskBio and Ginkgo Bioworks; 3 of its 3 listed competitors have raised funding.
Company details
Codexis was founded in 2002 and is headquartered in Redwood City, United States. Operations focus on biotechnology, where the proprietary CodeEvolver platform is used to identify and engineer novel enzymes for pharmaceutical manufacturing. Additional efforts include the development of biotherapeutics and the Enzyme-Catalyzed Oligonucleotide Synthesis platform for producing RNA oligonucleotide therapeutics. These activities support drug discovery and synthesis processes in the sector.
- Headquarters Redwood City, United States
- Employees 188
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website codexis.com
- Social LinkedIn X Facebook
- Legal Name Codexis, Inc.
- Annual Revenue$70.39 M (USD)18.61as on Dec 31, 2025
- Net Profit-$43.97 M (USD)32.63as on Dec 31, 2025
- EBITDA-$30.04 M (USD)40.19as on Dec 31, 2025
- Total Equity Funding$74.17M (USD)
in 9 rounds
- Latest Funding Round$50M (USD), Post-IPO
Jun 2019
- InvestorsChevron
& 7 more
- Employee Count188
Associated legal entities of Codexis
Codexis operates through Codexis Laboratories India Private Limited (under liquidation). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Codexis Laboratories India Private Limited CIN U24231KA2005PTC035895 | Under Liquidation | 23 Mar 2005 | Bangalore, Karnataka | 3 | View details |
Products & Services of Codexis
Codexis offers a comprehensive portfolio of products and services, including CodeEvolver Platform and ECO Synthesis Technology.
Platform for tailoring enzyme performance in biocatalysis applications.
Technology for enzymatic processes in oligonucleotide production.
Funding Insights of Codexis
Codexis has successfully raised a total of $74.17M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $74.17M
- Total Rounds 9
- Last Round Post-IPO — $50M
- First Round $25M
(Oct 2002)
- Investors Count 8
All 9 funding rounds of Codexis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $50M | Post-IPO | – | – | |
| Jun 2010 | $9.31M | Grant | – | – | |
| Oct 2007 | $600,000 | Series D | – | – | – |
| Aug 2007 | $1.57M | Series D | – | – | – |
| Aug 2006 | $37M | Series D | – | – | |
| Jun 2006 | $4.2M | Debt – Conventional | – | – | – |
| Nov 2005 | Series B | – | – | – | |
| Aug 2004 | $10M | Series B | – | – | – |
| Oct 2002 | $25M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in Codexis
Codexis has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Chevron, FirstMark and Maxygen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
| cmea.com | ||||
Government-backed investments are directed toward healthcare, fintech, and various sectors. | edbi.com | Singapore, Singapore | ||
Early-stage venture capital is invested in tech startups across sectors. | 1987 | firstmark.com | New York, United States | |
| pequotcap.com | ||||
Chevron Corporation is engaged in global energy production and sustainability. | 1879 | chevron.com | United States | |
Protein drugs are developed for chemotherapy-induced neutropenia treatment. | 1997 | maxygen.com | Redwood City, United States | |
Scientific and technical information is managed and disseminated by OSTI.GOV. | osti.gov | Oak Ridge, United States |
Investor details for Codexis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Codexis Laboratories India Private Limited (Codexis)
Codexis Laboratories India Private Limited is the primary company behind Codexis. The board of Codexis Laboratories India Private Limited currently have 3 directors; the longest-serving is Gordon Thomas Barclay Sangster, appointed in 2014. 12 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Gordon Thomas Barclay Sangster DIN 06965845 | Director | 05 Sep 2014 | 12 yrs 2 mo | Codexis Laboratories India Private Limited |
| Richard Alexander Sabalot DIN 07480669 | Director | 30 Mar 2016 | 10 yrs 7 mo | Codexis Laboratories India Private Limited |
| Mercedes Paras Reshke DIN 07480668 | Director | 30 Mar 2016 | 10 yrs 7 mo | Codexis Laboratories India Private Limited |
People of Codexis
77 people are tracked at Codexis (37 in leadership, 8 in board & advisors, 32 in team); the tracked headcount is 188.
| Name | Role | Group |
|---|---|---|
Stephen Dilly | CEO | Leadership |
Stefanie Minor | Director, Program Management And Sales Operations | Leadership |
Svetlana Sowers | Director, Business Development And Alliance Management | Leadership |
Maggie Angelova | Sr. Director, Business Development | Leadership |
Karen Frechou-Armijo | SVP & Head, Human Resources | Leadership |
Jason Hein | Sr. Director, Corporate Development & Portfolio Strategy | Leadership |
Omid Abtahi | Director, Supply Planning | Leadership |
Kathy Preston | Director Of Project Management | Leadership |
Cristine Mananquil | Director Of External Reporting | Leadership |
David Entwistle | Head Of Process Chemsitry | Leadership |
Nikki Kruse | Assoc Director, Structural Bioinformatics | Leadership |
Mathew Miller | Director, Life Science Technologies And Applications | Leadership |
Sridharan Govind | Director, Internal Manufacturing | Leadership |
Margie Borra-Garske | Assoc. Director, Protein Engineering | Leadership |
Oscar Alvizo | Sr Director Of Computational Biology | Leadership |
Justin Dassie | Senior Director Business Development | Leadership |
Callie Huitt-Roehl | Director | Leadership |
Britton Jimenez | Sr. Vice President, Commercial Operations | Leadership |
Lata Sircar | Associate Director, Fp&a | Leadership |
Asif Rahman | Director, Fermentation Technologies | Leadership |
57 more people are available in the full profile.
Complete people profiles for Codexis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Codexis
Codexis is a publicly listed company on the NASDAQ with ticker symbol CDXS in USA, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Apr 2010
- Listed onNASDAQ: CDXS
- Listed entityCodexis, Inc.
- Exchange sectorProcess industries
- ISINUS1920051067
- Share price$1.32 (-6.38% on the day) · 2026-10-13
- Market capitalisation$144.5M
- EPS (diluted, trailing year)$-0.34
- Volume (last session)820,523
Financials of Codexis
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $70.4M | -$44.0M | -$30.0M |
| 2024 | $59.3M | -$65.3M | -$50.2M |
| 2023 | $70.1M | -$76.2M | -$44.9M |
| 2022 | $138.6M | -$33.6M | -$21.5M |
| 2021 | $104.8M | -$21.3M | -$16.8M |
Balance sheet, profit and loss, cash flow and ratios of Codexis Laboratories India Private Limited are on its company page.
Detailed financial statements for Codexis
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Codexis
4 dated milestones of Codexis across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Codexis is founded.
- Funding First funding round of $25.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $50.0M.
Competitors of Codexis
Codexis has 3 listed competitors in our database, 3 of them funded. They include Amyris, AskBio and Ginkgo Bioworks.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. | ||
| ginkgobioworks.com | 2008 | Boston, United States | $795.75M | 1,218 | Gene editing-based cultured ingredients are provided for agriculture. |
Detailed competitors of Codexis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Codexis
The website of Codexis (codexis.com) receives about 6.2K visits a month and ranks #3,137,247 among all websites worldwide, #4,131 in Biotechnology and Pharmaceuticals.
- Monthly visits6.2K
▼ 4.6% vs previous month
- Unique visitors2.9K
per month
- Global rank#3,137,247
among all websites
- Category rank#4,131
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.6
- Average visit48 sec
- DevicesDesktop 46% · Mobile 54%
Websites whose visitors overlap most with Codexis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| arraybiopharma.com | 100% | View details | |||
| fibrogen.com | 98% | 6.2K | #2,827,257 | View details | |
| focusdx.com | 64% | View details | |||
| fluidigm.com | 35% | 1.1K | #14,860,207 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Codexis (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Codexis
Complete news archive for Codexis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Codexis
Codexis was founded in 2002.
Codexis is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Stephen Dilly is the CEO of Codexis, as recorded in our data.
Codexis is a funded company, having raised a total of $74.17M across 9 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Oct 2002.
Codexis has 188 employees.
Annual revenue of Codexis is $70.39M as on Dec 31, 2025.
Codexis was founded in 2002 and is headquartered in Redwood City, United States. Operations focus on biotechnology, where the proprietary CodeEvolver platform is used to identify and engineer novel enzymes for pharmaceutical manufacturing. Additional efforts include the development of biotherapeutics and the Enzyme-Catalyzed Oligonucleotide Synthesis platform for producing RNA oligonucleotide therapeutics. These activities support drug discovery and synthesis processes in the sector.
Codexis's top competitors include Amyris, AskBio and Ginkgo Bioworks.
Codexis offers CodeEvolver Platform and ECO Synthesis Technology.
Yes, Codexis is publicly traded on NASDAQ under the ticker symbol CDXS.
Codexis has 8 investors. Key investors include Chevron, FirstMark, Maxygen, Casdin Capital, and CMEA Capital.
Codexis operates through Codexis Laboratories India Private Limited.